Cargando…

1H-NMR metabolomics-based surrogates to impute common clinical risk factors and endpoints

BACKGROUND: Missing or incomplete phenotypic information can severely deteriorate the statistical power in epidemiological studies. High-throughput quantification of small-molecules in bio-samples, i.e. ‘metabolomics’, is steadily gaining popularity, as it is highly informative for various phenotypi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bizzarri, D., Reinders, M.J.T., Beekman, M., Slagboom, P.E., BBMRI-NL, van den Akker, E.B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8703237/
https://www.ncbi.nlm.nih.gov/pubmed/34942446
http://dx.doi.org/10.1016/j.ebiom.2021.103764
_version_ 1784621415110017024
author Bizzarri, D.
Reinders, M.J.T.
Beekman, M.
Slagboom, P.E.
BBMRI-NL
van den Akker, E.B.
author_facet Bizzarri, D.
Reinders, M.J.T.
Beekman, M.
Slagboom, P.E.
BBMRI-NL
van den Akker, E.B.
author_sort Bizzarri, D.
collection PubMed
description BACKGROUND: Missing or incomplete phenotypic information can severely deteriorate the statistical power in epidemiological studies. High-throughput quantification of small-molecules in bio-samples, i.e. ‘metabolomics’, is steadily gaining popularity, as it is highly informative for various phenotypical characteristics. Here we aim to leverage metabolomics to impute missing data in clinical variables routinely assessed in large epidemiological and clinical studies. METHODS: To this end, we have employed ∼26,000 (1)H-NMR metabolomics samples from 28 Dutch cohorts collected within the BBMRI-NL consortium, to create 19 metabolomics-based predictors for clinical variables, including diabetes status (AUC(5-Fold CV) = 0·94) and lipid medication usage (AUC(5-Fold CV) = 0·90). FINDINGS: Subsequent application in independent cohorts confirmed that our metabolomics-based predictors can indeed be used to impute a wide array of missing clinical variables from a single metabolomics data resource. In addition, application highlighted the potential use of our predictors to explore the effects of totally unobserved confounders in omics association studies. Finally, we show that our predictors can be used to explore risk factor profiles contributing to mortality in older participants. INTERPRETATION: To conclude, we provide (1)H-NMR metabolomics-based models to impute clinical variables routinely assessed in epidemiological studies and illustrate their merit in scenarios when phenotypic variables are partially incomplete or totally unobserved. FUNDING: BBMRI-NL, X-omics, VOILA, Medical Delta and the Dutch Research Council (NWO-VENI).
format Online
Article
Text
id pubmed-8703237
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-87032372022-01-04 1H-NMR metabolomics-based surrogates to impute common clinical risk factors and endpoints Bizzarri, D. Reinders, M.J.T. Beekman, M. Slagboom, P.E. BBMRI-NL van den Akker, E.B. EBioMedicine Article BACKGROUND: Missing or incomplete phenotypic information can severely deteriorate the statistical power in epidemiological studies. High-throughput quantification of small-molecules in bio-samples, i.e. ‘metabolomics’, is steadily gaining popularity, as it is highly informative for various phenotypical characteristics. Here we aim to leverage metabolomics to impute missing data in clinical variables routinely assessed in large epidemiological and clinical studies. METHODS: To this end, we have employed ∼26,000 (1)H-NMR metabolomics samples from 28 Dutch cohorts collected within the BBMRI-NL consortium, to create 19 metabolomics-based predictors for clinical variables, including diabetes status (AUC(5-Fold CV) = 0·94) and lipid medication usage (AUC(5-Fold CV) = 0·90). FINDINGS: Subsequent application in independent cohorts confirmed that our metabolomics-based predictors can indeed be used to impute a wide array of missing clinical variables from a single metabolomics data resource. In addition, application highlighted the potential use of our predictors to explore the effects of totally unobserved confounders in omics association studies. Finally, we show that our predictors can be used to explore risk factor profiles contributing to mortality in older participants. INTERPRETATION: To conclude, we provide (1)H-NMR metabolomics-based models to impute clinical variables routinely assessed in epidemiological studies and illustrate their merit in scenarios when phenotypic variables are partially incomplete or totally unobserved. FUNDING: BBMRI-NL, X-omics, VOILA, Medical Delta and the Dutch Research Council (NWO-VENI). Elsevier 2021-12-20 /pmc/articles/PMC8703237/ /pubmed/34942446 http://dx.doi.org/10.1016/j.ebiom.2021.103764 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bizzarri, D.
Reinders, M.J.T.
Beekman, M.
Slagboom, P.E.
BBMRI-NL
van den Akker, E.B.
1H-NMR metabolomics-based surrogates to impute common clinical risk factors and endpoints
title 1H-NMR metabolomics-based surrogates to impute common clinical risk factors and endpoints
title_full 1H-NMR metabolomics-based surrogates to impute common clinical risk factors and endpoints
title_fullStr 1H-NMR metabolomics-based surrogates to impute common clinical risk factors and endpoints
title_full_unstemmed 1H-NMR metabolomics-based surrogates to impute common clinical risk factors and endpoints
title_short 1H-NMR metabolomics-based surrogates to impute common clinical risk factors and endpoints
title_sort 1h-nmr metabolomics-based surrogates to impute common clinical risk factors and endpoints
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8703237/
https://www.ncbi.nlm.nih.gov/pubmed/34942446
http://dx.doi.org/10.1016/j.ebiom.2021.103764
work_keys_str_mv AT bizzarrid 1hnmrmetabolomicsbasedsurrogatestoimputecommonclinicalriskfactorsandendpoints
AT reindersmjt 1hnmrmetabolomicsbasedsurrogatestoimputecommonclinicalriskfactorsandendpoints
AT beekmanm 1hnmrmetabolomicsbasedsurrogatestoimputecommonclinicalriskfactorsandendpoints
AT slagboompe 1hnmrmetabolomicsbasedsurrogatestoimputecommonclinicalriskfactorsandendpoints
AT bbmrinl 1hnmrmetabolomicsbasedsurrogatestoimputecommonclinicalriskfactorsandendpoints
AT vandenakkereb 1hnmrmetabolomicsbasedsurrogatestoimputecommonclinicalriskfactorsandendpoints